Latest Isis Stories

CHICAGO, May 16, 2013 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Genomic Health Inc. (Nasdaq:GHDX), Sanofi (NYSE:SNY), Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN), Amgen Inc. (Nasdaq:AMGN) and Isis Pharmaceuticals, Inc. (Nasdaq:ISIS). (Logo:...

CARLSBAD, Calif., May 13, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 2013 UBS Global Healthcare Conference on Monday, May 20, 2013 at 9:00 a.m. ET in New York, NY. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay will be available on the Isis Web...

CARLSBAD, Calif., May 8, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the pricing of an underwritten public offering of 9,000,000 shares of its common stock, offered at a price to the public of $19.00 per share. The gross proceeds to Isis from this offering are expected to be $171.0 million, before deducting the underwriting discount and other estimated offering expenses payable by Isis. The offering is expected to close on or about May 14, 2013,...

CARLSBAD, Calif., May 7, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it intends to offer for sale 9 million shares of its common stock in an underwritten public offering. In connection with this offering, Isis intends to grant the underwriters an option to purchase an additional­­­­ 1.35 million shares of its common stock. All shares in the offering are being offered by Isis. The offering is subject to market conditions, and...

- Conference Call Webcast Tuesday, May 7, 4:30 p.m. ET at www.isispharm.com CARLSBAD, Calif., May 7, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported pro forma operating income of $4.5 million and pro forma net income of $1.2 million for the three months ended March 31, 2013 compared to a pro forma net operating loss of $16.2 million and a pro forma net loss of $21.7 million for the same period in 2012. The significant improvement in the Company's...

CARLSBAD, Calif., May 2, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Isis Pharmaceuticals' First Quarter 2013 Financial Results and Highlights Conference Call When: Tuesday, May 7, 2013 at 4:30 p.m. ET /1:30 p.m. PT Where: www.isispharm.com How: Live on the Internet. Simply log onto our Web site listed above. If you are unable to participate during...

Isis to Earn $3.5 Million Milestone Payment CARLSBAD, Calif., April 23, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 2 study of ISIS-SMN(Rx) in infants with spinal muscular atrophy (SMA). SMA is a severe and rare genetic neuromuscular disease characterized by muscle atrophy and weakness and is the most common genetic cause of infant mortality. The study, which will begin enrolling patients soon, is a Phase 2 study in eight...

CARLSBAD, Calif., April 22, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 12(th) Annual Needham Healthcare Conference on Tuesday, April 30, 2013 at 11:20 a.m. ET in New York, NY. A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. A replay will be available on the...

BASEL, Switzerland, and CARLSBAD, Calif., April 8, 2013 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and Isis Pharmaceuticals, Inc (NASDAQ: ISIS) today announced that they have formed an alliance to develop treatments for Huntington's disease (HD) based on Isis' antisense oligonucleotide (ASO) technology. This alliance combines Isis' antisense expertise with Roche's scientific expertise in developing neurodegenerative therapeutics. In addition, Isis and Roche will be...

The event will be held on Friday, April 5, 2013, from 7:00 – 9:00 PM at ISIS Canada headquarters in Toronto. Palo Alto, CA (PRWEB) April 03, 2013 Sofia University (formerly Institute of Transpersonal Psychology) professor Lisa Herman will conduct a lecture and presentation titled, “Between Hope and Despair: Co-Creating with Disturbing Images,” at the International School of Interdisciplinary Studies in Canada (ISIS Canada). The event will be held on Friday, April 5, 2013, from 7:00...